first quarter financial result conference call webcast zoetis host call today frank vice president investor relation zoetis presentation material additional financial table currently post investor relation section zoetis presentation slide manage viewer forward automatically addition replay call available approximately hour conclusion call dial investor relation section zoetis operator instruction pleasure turn floor frank begin frank vice president investor relation thank good morning everyone welcome zoetis first quarter earn call join today chief executive officer chief financial officer begin remind slide present call available investor relation section website remark today include forward look statement actual result could differ materially projection list description certain factor could cause result differ refer forward look statement today press release file include limit annual report form report form remark today also include reference certain financial measure prepare accordance generally accept account principle reconciliation financial measure directly comparable measure include financial table accompany earn press release company file date today also cite operational result exclude impact foreign exchange turn call chief executive good morning everyone hope love stay healthy able vaccinate already soon fortunate vaccination rate infection rate trend overall situation everywhere many country improve access vaccine control infection rate critical hurdle comprehensive global recovery extraordinary measure take many remain optimistic steady progress make beat pandemic also proud able zoetis small support global effort able keep colleague safe encourage assist vaccination possible continue serve customer care animal strong start execute strategy build innovative care portfolio expand market outside accelerate growth diagnostics first quarter grow line revenue operationally best quarter ever operational growth internationally growth lead international performance operational growth respectively exhibit strength companion animal livestock product sale total containment animal portfolio grow operationally base strength parasiticides dermatology product livestock portfolio grow operationally solid growth cattle swine fish product deeper care year since launch triple combination parasiticide exceed expectation receive customer plus penetration rate largest corporate account latest growth catalyst portfolio small animal parasiticides several successful innovation last year product make total sale first quarter include brand revolution believe ongoing market shift commerce another boost category help increase compliance month therapy direct consumer campaign continue show solid return investment market around world meanwhile dermatology portfolio lead demonstrate continue double digit growth excellent traction significant growth across range international market dermatology portfolio growth potential continue expand international customer base seek become common first line treatment veterinarian owner alike appreciate exceptional standard care product provide containment animal space also continue please diagnostics portfolio grow operationally first quarter grow point care diagnostic sale make excellent progress improve connectivity solution veterinary practice cloud base image platform receive positive customer feedback placement exceed expectation early launch also make progress reference integration look forward future expansion space internationally growth livestock drive performance cattle swine fish first quarter cattle product sale strong food service sector start recover generic competition projection later expect meanwhile swine benefit continue recovery swine fever thank unprecedented growth revenue continue financial discipline adaptability throughout adjust income grow operationally look ahead raise guidance operational growth full year revenue range unusually strong first quarter expect normalize revenue growth second half year tougher comparative quarter increase generic competition provide detail guidance update remark since begin year zoetis continue advance priority include milestone product life cycle innovation geographic expansion major brand since last earn announcement receive approval union first injectable monoclonal antibody alleviation pain associate osteoarthritis launch year osteoarthritis vastly underdiagnosed undertreated today limit option therapy difficulty recognize pain meanwhile monoclonal antibody alleviation pain launch great customer response owner reference increase activity social ability quality life continue discussion regard regulatory submission manufacture inspection anticipate approval product likely later year provide update revenue expectation product clarity approval time rollout plan also worth note second largest market term revenue zoetis recently receive approval several lead product vaccine anti infective cattle swine revolution plus latest parasiticide continue strengthen portfolio catalyst growth also maximize brand geographic expansion poultry expand line recombinant vector vaccine approval several smaller market parasiticides receive additional approval several smaller market term sustainability publish long term goal march specific commitment community animal planet build comprehensive rigorous approach drive care program goal include support unite nation sustainable development goal release detail goal initial progress sustainability report close fundamental growth driver industry continue show strong sustainable momentum adoption trend higher spend visit along increase medicalization rate market outside continue bode significant growth companion animal diagnostic portfolio globally feel confident companion animal business come last year launch innovative product define standard treatment expand global reach companion animal business total revenue last year grow base strength innovation investment growth continue expand livestock industry limit innovation cycle expect modest growth year livestock growth closely pandemic quickly foodservice industry recover zoetis also anticipate increase headwind generic competition expect life cycle innovation competitive strategy help mitigate impact livestock present challenge near term feel positive catalyst growth care diagnostics international market like continue lead companion animal parasiticide dermatology portfolio growth come bright future ahead monoclonal antibody pain diagnostics accelerate growth increase global footprint expand reference demonstrate potential image veterinary clinic internationally continue market significant growth potential swine product sizable opportunity increase medicalization expect major growth continue across companion animal livestock portfolio always remain confident zoetis diverse portfolio across geography continue pipeline innovative product life cycle innovation agility commitment colleague continue drive success beyond hand speak first quarter result update guidance full year executive vice president chief financial good morning everyone mention strong start year deliver substantial growth global basis across therapeutic area today focus comment first quarter financial result driver contribute performance update improve full year guidance first quarter generate revenue billion grow report basis operationally adjust income million increase report basis operationally operational revenue grow result entirely volume increase price flat quarter volume growth include line product product dermatology product companion animal product lead term growth grow operationally livestock grow operationally quarter performance companion animal drive parasiticide portfolio include sale certain market also growth dermatology product small animal vaccine diagnostics follow blockbuster sale year begin strong first quarter performance post revenue million grow sequentially quarter since launch underlie dynamic drive first quarter sale favorable significant future growth increase clinic penetration robust reorder rate within penetrate clinic like mention please performance broader parasiticide portfolio addition franchise significant growth revolution franchise market share within flea tick heartworm segment time high represent increase first quarter versus period prior year global sale dermatology portfolio million quarter grow operationally remain confident dermatology sale exceed billion year diagnostics portfolio grow lead increase consumable instrument revenue present challenge condition diagnostics business social distance restriction limit ability enter clinic increase market share however vast product portfolio commitment innovation ability leverage breadth medicine vaccine portfolio position grow faster overall diagnostics market livestock growth quarter primarily drive cattle swine business improve market condition recovery successful promotional activity lead increase sale across cattle portfolio addition later expect time generic entrant lead strong first quarter sale swine portfolio grow operationally large producer continue rebuild herd recover swine fever create significant demand product poultry sale decline first quarter producer expand lower alternative premium product decline poultry partially temper growth cattle swine fish revenue growth segment quarter revenue grow companion animal product grow livestock sale decline companion animal ownership spend trend remain promise severe weather cause slight decline clinic traffic quarter revenue visit addition ownership increase trend toward younger demographic younger owner typically spend care driver increase revenue visit create robust demand diverse portfolio small animal parasiticide portfolio largest contributor companion animal growth grow quarter diagnostics dermatology product small animal vaccine also contribute growth continue perform sale million franchise generate sale million quarter number brand flea tick heartworm segment companion animal diagnostic sale increase quarter continue recovery clinic favorable prior year comparative period lead significant growth point care consumable revenue dermatology sale million quarter grow significant growth livestock decline quarter drive primarily poultry producer switch lower alternative unfavorably impact business swine also decline quarter attribute almost entirely favorable nonrecurring government purchase occur cattle grow quarter promotional program time generic entrant drive growth across product portfolio growth cattle partially offset decline poultry swine summarize performance strong remain favorable companion animal market environment offer broadest innovative product portfolio although livestock decline quarter expectation decline year encourage series foodservice trend increase school business reopen revenue international segment grow operationally quarter companion animal revenue grow operationally livestock revenue grow operationally strength companion animal fuel continue trend adoption increase standard care owner investment advertise drive growth across parasiticide dermatology portfolio companion animal diagnostics grow quarter lead increase point care consumable revenue second consecutive quarter double digit increase instrument placement revenue begin early experience program monoclonal antibody alleviation pain feedback program extremely positive solidify view long term potential product launch currently feline monoclonal antibody begin early experience program launch follow third quarter provide owner innovative therapy address largest unmet need animal health international livestock business double digit growth across exception poultry grow single digit quarter swine revenue grow operationally lead growth mark third consecutive quarter swine growth excess additional outbreak strain swine fever occur believe contain specific region limit number customer cattle grow operationally quarter result market campaign account penetration favorable export market condition several emerge market fish portfolio deliver another strong quarter grow operationally drive strong performance time seasonal vaccination protocol acquisition fish group major market grow first quarter many double digit total sale grow operationally addition significant growth swine deliver operational growth companion animal grow operationally quarter sale lead oral parasiticide market drive operational increase companion animal overall international segment deliver strong result demonstrate value substantial geographic diversification companion animal business benefit favorable trend rise medicalization rate outside swine largest growth driver international livestock business contribution broad base growth across move rest adjust gross margin increase basis point report basis compare prior year result favorable product partially offset foreign exchange include freight adjust operate expense increase operationally result increase compensation relate advertise promotion expense partially offset reduction result adjust effective rate quarter increase basis point drive reduction favorable discrete item compare prior year comparable quarter partially offset favorable impact jurisdictional earn adjust income adjust dilute grow operationally quarter primarily drive revenue growth resume share repurchase program first quarter repurchase approximately million worth share along dividend share repurchase critical component shareholder distribution strategy remain strong liquidity position highly cash generative result expect able execute investment priority include direct consumer advertise internal external business development still return excess cash shareholder move update guidance raise result first quarter performance please note guidance reflect foreign exchange rate late revenue raise narrow guidance range project revenue billion billion operational revenue growth full year versus guidance adjust income expect range billion billion represent operational growth compare prior guidance adjust dilute expect range report dilute range assumption change materially since guidance provide call however current view face competition dermatology product second half fourth quarter call mention anticipate growth heavily weight toward first half year like take time expand upon expect first half growth materially outpace growth second half year primarily result sale favorable comparative period relate subsequently expect growth moderate second half year result increase generic competition challenge comparative period demand first half work system second half summarize move deliver strong operational bottom line growth first quarter significant gain companion animal livestock across nearly every therapeutic area geography addition raise narrow full year guidance growth moderate back half year reason outline expect grow faster market feel positive position sustain growth beyond year hand thing operator open line question operator